Clinical trial · Interventional
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS)
NCT07412028CI-TRIAL-00121329ANDROLIPOrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diagnostic case-control study (1 case for 2 controls). Inclusion of patients with severe insulin resistance syndrome of genetic origin, then inclusion of controls: patients examined for PCOS in day hospital with matching age (+/- 5 years) and Body mass index (+/- 5kg/m2).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Familial Partial Lipodystrophy | — | UNRESOLVED | — |
| LMNA (LaMin Nuclear A) Related Disorders | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological analysis | Other | — | UNRESOLVED |
| Genetic analysis | Genetic | — | UNRESOLVED |
| imaging test | Other | — | UNRESOLVED |
| Standard intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Case
- description
- Patient with a Lipodystrophy Familial Partial due to a known pathogenic variant of the LMNA gene
- interventionNames
- Genetic: Genetic analysis
- Other: Biological analysis
- Other: imaging test
- type
- OTHER
- label
- Control
- description
- Patient consulting for polycystic ovary syndrome in day hospital matched on age +/-5 years and BMI+/-5 kg/m2
- interventionNames
- Other: Standard intervention
Primary outcomes (4)
- measure
- Measure of Insulinemia rate during an orally induced hyperglycemia
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged ≥ 18 years and \< 45 years ; * Discontinuation of estrogen-progestin therapyfor at least 3 months ; * Signed informed consent ; * Social security affiliation. Case (n=25): \- Patient with a lipodystrophic syndrome due to a known pathogenic variant of the LMNA gene. Control (n=50), : \- patient consulting for polycystic ovary syndrome (PCOS according to the Rotterdam criteria) in day hospital matched on age +/-5 years and BMI+/-5 kg/m2. Exclusion Criteria: * \- Severe renal insufficiency (GFR \< 30 ml/min) ; * Hepato-cellular insufficiency (TP \< 50%) ; * Taking corticosteroids or antiretrovirals ; * Menopausal women ; * Taking estrogen-progestin therapy; * Diabetic patients on insulin : type 1 diabetes or pancreatectomised patients * Other known causes of hyperandrogenism (21-hydroxylase block, Cushing's syndrome, ovarian tumor). * Pregnant woman * Breastfeeding woman
References
Publications (0)
Data not yet available
No reference posted for this study.